• Publications
  • Influence
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
The hypothesis that CYP2D6 genotype predicts clinical benefit of adjuvant tamoxifen treatment among postmenopausal breast cancer patients is not supported.
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Letrozole (2.5 mg once daily) is revealed to be a more potent suppressor of total-body aromatization and plasma estrogen levels compared with anastrozoles in postmenopausal women with metastatic breast cancer.
The pharmacology of letrozole
Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen
  • M. Dowsett, B. Haynes
  • Biology, Medicine
    The Journal of Steroid Biochemistry and Molecular…
  • 1 September 2003
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).
Results indicate that CB7598, CB7630 or CB7627 may be useful in the treatment of hormone-dependent prostatic cancers and no inhibition of corticosterone production by these steroidal compounds is indicated.
Intratumoral Estrogen Disposition in Breast Cancer
Uptake due to binding to the ER, rather than intratumoral estrogen synthesis by aromatase or sulfatase, is the single most important correlate and a probable determinant of intratumoran E2.
Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Higher PgR and Ki67 levels are significantly associated with increased and decreased TTF, respectively, in ER-positive patients receiving AI treatment of advanced disease.